The Rise of Biotech Royalties

Clarke Futch is a co-founder, Managing Partner and Chairman of the Investment Committee at Healthcare Royalty Partners, an investment firm that purchases royalties and uses debt-like instruments to generate non-correlated return streams from biopharmaceutical assets. The firm is a leader in the space and has invested over $3 billion in 70 investments since its founding 14 years ago.

Our conversation covers Clarke's background in investment banking and path to pharmaceutical royalties in the earliest days of the business. We discuss the nature of the opportunity, the reason why it exists, and how it works, and the team in place at Healthcare Royalty Partners that makes it happen.

We then turn to the investment process, covering sourcing, screening criteria, due diligence, deal structure, portfolio construction, competitive landscape, risks, and opportunities in the current market.

Clarke offers an inside look at one of the more intriguing modern investment strategies with great insight and examples along the way.